Ortho Evra - Additional Info

(Page 5)

contraceptives. Br J Cancer 1983;48:437-440.

53. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986; 292:1355-1357.

54. Forman D, Vincent TJ, Doll R. Cancer of the liver and oral contraceptives. Br Med J 1986; 292:1357-1361.

55. Harlap S, Eldor J. Births following oral contraceptive failures. Obstet Gynecol 1980; 55:447-452.

56. Savolainen E, Saksela E, Saxen L. Teratogenic hazards of oral contraceptives analyzed in a national malformation register. Am J Obstet Gynecol 1981: 140:521-524.

57. Janerich DT, Piper JM, Glebatis DM. Oral contraceptives and birth defects. Am J Epidemiol

1980; 112:73-79.

58. Ferencz C, Matanoski GM, Wilson PD, Rubin JD, Neill CA, Gutberlet R. Maternal hormone

therapy and congenital heart disease. Teratology 1980; 21:225-239.

59. Rothman KJ, Fyler DC, Goldblatt A, Kreidberg MB. Exogenous hormones and other drug exposures of children with congenital heart disease.

Am J Epidemiol 1979; 109:433-439.

60. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors. Lancet 1973;

1:1399-1404.

61. Royal College of General Practitioners: Oral contraceptives and health. New York, Pittman 1974.

62. Layde PM, Vessey MP, Yeates D. Risk of gallbladder disease: a cohort study of young women attending

family planning clinics. J Epidemiol Community Health 1982; 36:274-278.

63. Rome Group for Epidemiology and Prevention of Cholelithiasis (GREPCO): Prevalence of gallstone disease in an Italian adult

female population. Am J Epidemiol 1984; 119:796-805.

64. Strom BL, Tamragouri RT, Morse ML, Lazar EL, West SL, Stolley PD, Jones JK. Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther 1986; 39:335-341.

65. Wynn V, Adams PW, Godsland IF, Melrose J, Niththyananthan R, Oakley NW, Seedj A. Comparison of effects of different combined oral contraceptive formulations on carbohydrate and lipid metabolism.

Lancet 1979; 1:1045-1049.

66. Wynn V. Effect of progesterone and progestins on carbohydrate metabolism.

In: Progesterone and Progestin. Bardin CW, Milgrom E, Mauvis-Jarvis P. eds. New York, Raven Press

1983; pp. 395-410.

67. Perlman JA, Roussell-Briefel RG, Ezzati TM, Lieberknecht G. Oral glucose tolerance

and the potency of oral contraceptive progestogens. J Chronic Dis 1985;38:857-864.

68. Royal College of General Practitioners’ Oral Contraception Study: Effect on hypertension and benign breast disease of progestogen

component in combined oral contraceptives. Lancet 1977; 1:624.

69. Fisch IR, Frank J. Oral contraceptives and blood pressure. JAMA 1977; 237:2499-2503.

70. Laragh AJ. Oral contraceptive induced hypertension-nine years later. Am J Obstet Gynecol 1976; 126:141-147.

71. Ramcharan S, Peritz E, Pellegrin FA, Williams WT. Incidence of hypertension in the Walnut Creek Contraceptive Drug Study cohort: In: Pharmacology of steroid contraceptive drugs. Garattini S, Berendes HW. Eds. New York, Raven Press, 1977; pp. 277-288, (Monographs

of the Mario Negri Institute for Pharmacological Research Milan.)

72. Stockley I. Interactions with oral contraceptives. J Pharm 1976;216:140-143.

73. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Oral contraceptive use and the risk of ovarian cancer. JAMA 1983; 249:1596-1599.

74. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development: Combination oral contraceptive use and the risk of endometrial cancer. JAMA 1987; 257:796-800.

75. Ory HW. Functional ovarian cysts and oral contraceptives: negative association confirmed surgically. JAMA 1974; 228:68-69.

76. Ory HW, Cole P, MacMahon B, Hoover R. Oral contraceptives and reduced risk of benign breast disease. N Engl J Med

1976; 294:419-422.

77. Ory HW. The noncontraceptive health benefits from oral contraceptive use. Fam Plann Perspect 1982; 14:182-184.

78. Ory HW, Forrest JD, Lincoln R. Making choices: Evaluating the health risks and benefits of birth control methods. New York, The Alan Guttmacher Institute, 1983; p.1.

79. Schlesselman J, Stadel BV, Murray P, Lai S. Breast cancer in relation to early use of oral contraceptives. JAMA 1988; 259:1828-

1833.

80. Hennekens CH, Speizer FE, Lipnick RJ, Rosner B, Bain C, Belanger C, Stampfer MJ, Willett W, Peto

R. A case-control study of oral contraceptive use and breast cancer. JNCI 1984; 72:39-42.

81. LaVecchia C, Decarli A, Fasoli M, Franceschi S, Gentile A, Negri E, Parazzini F, Tognoni G. Oral contraceptives and cancers

of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer 1986; 54:311-

317.

82. Meirik O, Lund E, Adami H, Bergstrom R, Christoffersen T, Bergsjo P. Oral contraceptive use and breast

cancer in young women. A Joint National Case-control study in Sweden and Norway. Lancet 1986; 11:650-

654.

83. Kay CR, Hannaford PC. Breast cancer and the pill-A further report from the Royal College of General

Practitioners’ oral contraception study. Br J Cancer 1988;58:675-680.

84. Stadel BV, Lai S, Schlesselman JJ,Murray P. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception 1988; 38:287-299.

85. Miller DR, Rosenberg L, Kaufman DW, Stolley P, Warshauer ME, Shapiro S. Breast cancer before

age 45 and oral contraceptive use: New Findings. Am J Epidemiol 1989; 129:269-280.

86. The UK National Case-Control Study Group, Oral contraceptive use and breast cancer risk in young women. Lancet 1989; 1:973-

982.

87. Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives.

Contraception 1989; 40:1-38.

88. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives

and breast cancer: latest findings in a large cohort study. Br J Cancer 1989; 59:613-617.

89. Jick SS, Walker AM, Stergachis A, Jick H. Oral contraceptives and breast cancer. Br J Cancer 1989; 59:618-621.

90. Anderson FD, Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives.

Acta Obstet Gynecol Scand 1992; 156 (Supplement):15-21.

91. Chapdelaine A, Desmaris J-L, Derman RJ. Clinical evidence of minimal androgenic activity of norgestimate. Int J Fertil 1989; 34(51):347-352.

92. Phillips A, Demarest K, Hahn DW, Wong F, McGuire JL. Progestational and androgenic receptor binding

affinities and in vivo activities of norgestimate and other progestins. Contraception 1989; 41(4):399-409.

93. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used

in contraceptives. Contraception 1987; 36(2):181-192.

94. Janaud A, Rouffy J, Upmalis D, Dain M-P. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel Acta Obstet Gynecol Scand 1992; 156 (Supplement):34-38.

95. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis

of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer

from 54 epidemiological studies. Lancet 1996; 347:1713-1727.

96. Palmer JR, Rosenberg L, Kaufman DW, Warshauer ME, Stolley P, Shapiro S. Oral Contraceptive Use and Liver Cancer. Am J Epidemiol 1989;130:878-882.

97. Lewis M, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M on behalf of

Transnational Research Group on Oral Contraceptives and Health of Young Women. Third generation oral contraceptives

and risk of myocardial infarction: an international case-control study. Br Med J, 1996;312:88-90.

98. Vessey MP, Smith MA, Yeates D. Return of fertility after discontinuation of oral contraceptives: influence of

age and parity. Brit J Fam Plan; 1986; 11:120-124.

99. Back DJ, Orme M.L’E. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990; 18:472-484.

100. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997 Mar;38(3):317-323.

101. Shenfield GM. Oral Contraceptives. Are drug interaction of clinical significance? Drug Saf 1993 Jul;9(1):21-37.

102. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR. Effect of ritonavir on the pharmacokinetics

of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998;46(2):111-116.

103. Improving access to quality care in family planning: Medical eligibility criteria for contraceptive use. Geneva,

WHO, Family and Reproductive Health, 1996 (WHO/FRH/FPP/96.9).

104. Skolnick JL, Stoler BS, Katz DG, Anderson WH. Rifampicin, oral contraceptives and pregnancy. J Am Med Assoc 1976;236-1382.

105. Henney JE. Risk of drug interactions with St. John’s Wort. JAMA 2000;283(13).

106. Lahteennmaki P et al, Coagulation factors in women using oral contraceptives or intrauterine devices immediately after abortion. American Journal of Obstetrics and Gynecology, (1981); 141: 175-179.